Stockscreener 앱 받기
33.16
0.39%
-0.13
전일 마감가:
$33.29
열려 있는:
$33.52
하루 거래량:
989.05K
Relative Volume:
0.48
시가총액:
$5.48B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
17.01
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-5.01%
1개월 성능:
+13.76%
6개월 성능:
+15.82%
1년 성능:
-7.89%
1일 변동 폭
$33.09
$34.27
1주일 범위
$33.04
$35.34
52주 변동 폭
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
33.16 | 5.50B | 1.51B | 333.35M | 315.22M | 1.95 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Is Alkermes plc a top pick in the sectorCEO Change & Weekly Stock Performance Updates - mfd.ru
Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals - CHEManager
Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market - marketscreener.com
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - BioSpace
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market - TradingView
Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc. - Bitget
Alkermes Acquires Avadel Pharmaceuticals - Contract Pharma
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement - marketscreener.com
Alkermes Completes Acquisition and Delisting of Avadel Pharmaceuticals - TipRanks
Alkermes Acquires Avadel to Expand Product Portfolio - Intellectia AI
Avadel Pharmaceuticals Terminates Multiple Agreements Following Alkermes Acquisition - TradingView
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans - Stock Titan
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio - Sleep Review
Understanding the Setup: (ALKS) and Scalable Risk - Stock Traders Daily
Alkermes to report fourth quarter and year-end financial results on Feb. 25, 2026 - MSN
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire
Alkermes earnings up next as sleep strategy takes shape - Investing.com
Can Alkermes plc stock surprise with earnings upsideEarnings Growth Summary & Stock Portfolio Risk Management - mfd.ru
Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes - TipRanks
Alkermes (ALKS) Set to Finalize Acquisition of Avadel Pharmaceuticals - GuruFocus
Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing - The Manila Times
Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan
Alkermes Increases Offer for Avadel Acquisition - MSN
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
History Review: Will Alkermes plc outperform its industry peersJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS - MarketBeat
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Finviz
Stop Loss: Is Alkermes plc benefiting from interest rate changesPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Alkermes (ALKS) Projected to Post Earnings on Wednesday - MarketBeat
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock - MarketBeat
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares - MarketBeat
Alkermes plc (ALKS) Stock Analysis: Navigating a 29% Potential Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome - Finviz
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
The Technical Signals Behind (ALKS) That Institutions Follow - Stock Traders Daily
Are options traders betting on a big move in Alkermes stock? - MSN
Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum - Yahoo Finance
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 02 '26 |
Sale |
33.93 |
9,000 |
305,384 |
57,740 |
| Cooke Shane | Director |
Feb 02 '26 |
Option Exercise |
31.64 |
61,200 |
1,936,368 |
164,944 |
| Cooke Shane | Director |
Feb 02 '26 |
Sale |
34.57 |
61,200 |
2,115,673 |
103,744 |
1.19%
0.83%
자본화:
|
볼륨(24시간):